Pfizer (PFE) Director Joseph Echevarria Receives Award

What Happened

• Joseph Echevarria, a member of Pfizer's Board of Directors, was granted 1,613.185 units (phantom shares) on September 25, 2026. The units are recorded at $28.67 each, for a total grant value of $46,250. The filing lists this transaction as an award/grant (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date and price: 2026-09-25; 1,613.185 units at $28.67 per unit (total $46,250).
• Transaction type: Award/Grant of derivative units (code A).
• Shares/units owned after transaction: Not specified in this Form 4 filing.
• Footnotes: F1 — each unit equals one phantom share of common stock. F2 — units represent deferred director compensation (including dividend equivalents) that will be settled in cash or common stock at the director’s election following retirement from the Board.
• Filing timeliness: Form 4 filed on 2026-09-29 (within the two-business-day window for reporting such transactions).

Context

• This was a deferred compensation grant to a director (a non-market transaction) and should be viewed as compensation, not a straightforward buy or sell signaling immediate market sentiment. The award is a derivative entitlement (phantom shares) that will convert to cash or stock later according to the director’s election.